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Abstract
Aim—Both hyperglycemia and hyperlipidemia increase oxidative stress, and contribute to the
development of diabetic nephropathy (DN). We investigated effects of α-lipoic acid, a natural
antioxidant and a cofactor in the multienzyme complexes, on the development of DN in diabetic
apolipoprotein E-deficient mice.
Methods—Twelve-weeks-old male apoE−/− mice on C57BL/6J genetic background were made
diabetic with injections of streptozotocin (STZ). STZ-treated diabetic apoE−/− mice and non-
diabetic control were fed with a synthetic high fat (HF) diet with or without LA supplementation.
Multiple parameters including plasma glucose, cholesterol, oxidative stress markers, cytokines,
and kidney cortex gene expression, and glomerular morphology were evaluated.
Results—LA supplementation markedly protected the beta cells and reduced cholesterol levels,
attenuated albuminuria and glomerular mesangial expansion in the diabetic mice. Reno-protection
by LA was equally effective regardless of whether the dietary supplementation was started 4
weeks before, simultaneously with, or 4 weeks after the induction of diabetes by STZ. LA
supplementation significantly improved DN and oxidative stress in the diabetic mice. Severity of
albuminuria was positively correlated with level of thiobarbituric acid reactive substances
(TBARs) in the kidney (r2=0.62, P<0.05). Diabetes significantly changed the kidney expression of
Rage, Sod2, Tgfb1 and Ctgf, Pdp2, nephrin and Lias. LA supplementation corrected these changes
except that it further suppressed the expression of the Lias gene coding for lipoic acid synthase.
Conclusions—Our data indicate that LA supplementation effectively attenuates the
development and progression of DN through its antioxidant effect as well as enhancing glucose
oxidation.
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Diabetes mellitus (DM) is the leading cause of end-stage renal disease and the relative risk
for cardiovascular diseases is 10-fold higher for type 1 diabetic patients with nephropathy
compared to those without diabetic nephropathy (Tuomilehto, et al., 1998). Proteinuria, an
indicator of underlying diabetic nephropathy, usually worsens with progression of diabetic
kidney disease. Progression of kidney disease is characterized by declining glomerular
filtration rate and kidney structural changes, including thickening of the basement
membranes, mesangial sclerosis, and arteriolar hyalinosis.
Hyperglycemia is a major cause of increased glycation of protein and lipid that, in turn,
enhance the generation of reactive oxygen species (ROS) (Lee, et al. 2010, Aljofan & Ding,
2010). Thus, diabetes is usually accompanied by both an increased production of ROS and
impaired antioxidant defenses leading to increased oxidative stress that is considered
important in the development and progression of diabetes and its complications (Baynes &
Thorpe, 1999). Despite current recommendations for management of diabetic complications,
including administration of angiotensin converting enzyme inhibitors (ACEIs) or
angiotensin receptor antagonists (ARBs) to control proteinuria and attenuate progression of
chronic kidney disease (CKD) to end stage kidney disease (ESRD) [Kidney Disease
Outcome Quality Initiative (KDOQI) recommendations], prevalence of CKD secondary to
diabetes continues to increase (United States Renal Data Systems [USRDS] 2009; World
Health Organization [WHO]). Accordingly, there has been increasing interest in the
protective function of dietary antioxidants as potential adjunctive therapy to prevent diabetic
complication.
In diabetics with suboptimal glycemic control, hyperlipidemia may develop. In addition,
even in subjects with optimal glycemic control, abnormal lipid profile that is potential
atherogenic may exist. Indeed, hyperlipidemia is now considered an independent and major
determinant of progression of renal disease in diabetes (Rosario & Prabhakar, 2006). In this
regard, an association between high consumption of saturated fat and albuminuria in type 1
diabetic patients has been reported (Riley & Dwyer, 1998).
Alpha-lipoic acid (1, 2-dithiolane-3-pentanoic acid, LA) is a natural antioxidant and a
cofactor for mitochondrial α-ketoacid dehydrogenases (Reed, 1998), and consequently may
work as a regulator of glucose metabolism (Packer, et al., 1995). LA is synthesized in
mitochondria and, as well, may be derived from food. It is noteworthy that plasma LA levels
are decreased in diabetic patients (Kleemann, et al., 1989). Interestingly, accumulating
evidence suggests that LA supplementation is beneficial in both types 1 and 2 diabetes and,
for diabetic complications in patients and animals (Jacob, et al., 1999; Ziegler 2004;
Melhem, et al., 2002; Yi & Maeda 2006). The present study examined the effect of dietary
LA supplementation on diabetes-induced kidney damage in apoE−/− mice, an animal model
previously demonstrated to have a series of pathological conditions including dyslipidemia
and atherosclerosis. Hyperlipidemia per se, is associated with development of early renal
lesions in apoE−/− mice (Wen, et al., 2002). Mice were rendered diabetic by intraperitoneal
(IP) administration of low doses of STZ over 5 days, an established approach for inducing
type 1 diabetes mellitus (Kromann et al., 1982). Given the above features, STZ-induced
diabetic ApoE−/− mice fed high fat diet were used in our studies to accelerate DN and
probe the role of dyslipidemia in DN development (Erdely, et al., 2009; Cui, et al., 2009;
Kasiske et al. (1990)). We here show that dietary LA supplementation led to significant
changes in biomarkers of oxidative stress and reduced kidney damage in diabetic apoE−/−
mice. The effect was associated with the reduction of plasma levels of glucose, cholesterol,
and IL-6, and changes in expression of nephrin, Rage, Sod2, Pdp2, Lias, Tgfb1 and Ctgf in
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the kidney. The reno-protective effect of LA supplementation was equally effective
regardless of whether the supplement ation was given prior to, simultaneously or after the
induction of diabetes by STZ.
2. Materials and Methods
2.1. Experimental design
All animal experiments were carried out under protocols approved by the Institutional
Animal Care and Use Committee of the University of North Carolina at Chapel Hill. One
hundred twenty-five male apoE−/− mice on C57BL/6J genetic background (12 weeks-old)
were randomly divided into 4 groups: diabetic and control groups, with or without LA
supplementation. Mice were made diabetic with multiple intraperitoneal injections of STZ at
a low dose (40 mg/kg body weight in 0.1M citrate buffer, pH 4.5, (Sigma, St. Louis) to
avoid nephrotoxic effects, following the protocol by the Animal Models of Diabetic
Complications Consortium. The control group received buffer alone. Mice with blood
glucose levels higher than 300 mg/dl at 4 week after the STZ treatment were considered to
be diabetic. All mice were maintained on regular chow until being switched to a synthetic
high fat (HF) diet containing 21% (w/w, or 45% calories) fat, 0.05% cholesterol, 20%
sucrose (Research Diets, Inc. New Brunswick, NJ), with or without 200 mg/kg body weight
of racemic LA (Sigma, St. Louis, MO). In order to test whether dietary LA supplementation
can attenuate STZ-induced diabetes and whether different timing of LA supplementation can
produce different protective and/or therapeutic effect, three sets of experiments were carried
out: pre-STZ group in which LA supplementation was started 4 weeks before STZ injection;
co-STZ group in which the LA-supplemented diets were initiated simultaneously with the
STZ injection; and post-STZ group to which the LA-supplemented diets were provided
starting at 4 weeks after the initiation of the STZ injection. Approximately 10% of diabetic
mice on HF diet without LA became lethargic and were euthanized. Remaining animals
were sacrificed at 20 weeks after STZ treatment.
2.2. Biochemical analyses
Mice were fasted for 4 hours and blood samples were collected from the orbital sinus.
Systolic pressure was measured in conscious mice using a computerized noninvasive tail
cuff system (Visitech Systems, Cary. NC). At 3 and 5 months after the STZ injection, mice
were individually placed in metabolic cages for three consecutive days to monitor their
water and food consumption, urine volume, and body weight. Immediately after mice were
euthanized by an overdose of tribromoethanol, the right kidneys were quick-frozen in liquid
N2 and stored at −80°C. Tissues were rinsed with isotonic saline and homogenized in
phosphate-buffered saline (0.1mol/L, pH 7.4). The protein was measured by the Bradford
method (Bio-Rad, Hercules, CA) with bovine serum albumin as the standard.
Plasma glucose, cholesterol and triglyceride were measured using the kits from Wako
(Richmond, VA). Plasma and tissue lipid peroxide content was determined using TBARS
assay (Lapenna et al., 2001) with malondialdehyde as the standard. Erythrocyte GSH levels
were determined by using an assay kit (Calbiochem, San Diego, CA). Urinary 8-isoprostane
and albumin were determined using the EIA kit from Cayman (Ann Arbor, MI, USA) and
from Exocel Inc. (Philadelphia, PA), respectively. Superoxide dismutase (SOD) activity in
kidney cortex was measured by using superoxide dismutase assay kit for all three types of
SOD (Cayman). Advanced glycation end-products (AGEs) was measured as Nε-
(carboxymethyl) lysine (CML), which was determined in serum and kidney homogenates
with ELISA (CycLex Co., Ltd.,Nagano, Japan). Serum TNF-α and IL-6 were measured
using the Luminex-100 system (Luminex Corporation, Austin, Texas) and analyzed with
Flowmetrix software (Luminex) according to the manufacturer’s protocols.
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Paraffin sections (3 µm thick) were stained with H&E and Periodic acid Schiff (PAS).
Mesangial matrix expansion (MME) was derived from assessment of 100 glomeruli of 5
diabetic and 5 non-diabetic mice per dietary group. PAS-positive regions in mesangial zones
as well as the total glomerular tuft area were quantitatively measured using NIH Image J
program 1.34 (http://rsb.info.nih.gov/ij). A ratio of PAS positive mesangial zone over total
glomerular tuft area was calculated to evaluate the size of the MME. For transmission
electron microscopy (TEM), sections were prepared in the UNC Pathology Core Facility and
examined with LEO 910 electron microscope (LEO Electron Microscopy Inc. Thornwood,
New York). Immunostaining of the insulin positive cells of the pancreatic tissues was
determined as previously described (Yi & Maeda, 2006).
2.4. RT-PCR
Total RNA was extracted from kidney cortex using TRIzol reagent (Vitrogen, Carlsbad,
CA) according to the manufacturer’s protocol. Gene expressions were determined using
real-time quantitative reverse transcription PCR (Applied Biosystems, Foster City, CA) with
β-actin as the reference gene.
2.5. Statistical analysis
All the biochemical assays were carried out in duplicates. Statistical analysis was performed
with JMP software (SAS Cary NC). Diabetes effect, LA effect and their interaction were
analyzed using two-way ANOVA, and Tukey-Kramer HSD test was applied for post-hoc
pair-wise comparisons. Time effect was analyzed by MANOVA for repeated measurement.
When there were no statistical effects of the dietary groups, data from the three dietary
groups were combined and analyzed jointly.
3. Results
3.1. Timing of LA administration
Plasma glucose levels in the initial stage of diabetes (at 4 weeks after STZ injection) were
not significantly different among three groups, nor between diabetic mice with and without
LA supplementation (P=0.74 for the three groups, P=0.06 for diabetic mice with LA versus
without LA, by two-way ANOVA analysis). Plasma glucose levels in all diabetic mice
gradually decreased during the study period, and LA supplementation accelerated this
process (Figure 1). In pre-STZ group, plasma glucose values from the diabetic mice with LA
were significantly lower than those in diabetic mice without LA, and the difference was
noticeable as early as 12 weeks after initial STZ injection (Figure 1A, P<0.003 for overall
LA effect by ANOVA ). In contrast, in the co-STZ and post-STZ groups, LA
supplementation did not influence plasma glucose levels before 20 weeks (Figure 1B and
1C).
Morphometric quantification of the ratio of insulin-immunoreactive areas to total islet areas
in diabetic fed LA showed that 28.9 ± 1.4% of islets were staining positive for insulin in the
pre-STZ group, 21.4 ± 2.0 % in the co-STZ group and 22.6±2.8% in the post-STZ group
(Figure 1D). Insulin reactive area in the diabetic mice without LA was not significantly
lower than the mice with LA, and pre-STZ group had the highest survival β cells among the
three groups. No pathological changes were observed in non-diabetic mice.
STZ-induced diabetic mice that did not receive LA lost weight, but the diabetic mice
administered LA were able to partially maintain their body weight (P<0.01, Table 1). In
addition, LA supplementation significantly slowed the HF diet-induced weight gain in the
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non-diabetic mice, although there was no significant difference of daily dietary intake in the
non-diabetic mice with or without LA (Table 1).
Although hyperglycemia and weight loss were attenuated in mice within the pre-STZ group,
in association with more survival β-cells, data from mice within three dietary groups were
not significantly affected by the timing of LA administration. Therefore, we analyzed these
data together in the following sections.
3.2. Oxidative stress markers in plasma, urine and kidneys
Diabetes significantly increased oxidative stress, as reflected by reduction in erythrocyte
GSH and increases in plasma TBARS; LA supplementation ameliorated these changes
(Table 1). Similarly, AGEs and TBARS in kidney cortex, as well as urinary 8-isoprostane
were significantly increased by diabetes, but LA supplementation attenuated these increases
(Figure 2A, 2B and 2D). Total SOD activity in kidney cortex was decreased in diabetic
mouse, and treatment with dietary LA partially restored its activity (Figure 2C). Taken
together, these data strongly suggested that dietary LA supplementation significantly
suppressed oxidative stress in diabetes.
3.3. Plasma cytokines
In order to evaluate changes in inflammatory mediators in the diabetic state and explore
potential anti-inflammatory effects of LA, we monitored serum concentrations IL-6 and
TNF-α in each mouse in the course of 5-month. IL-6 levels in the diabetic mice significantly
increased at 3 months after STZ injection (data not shown) and increased 10-fold at 5
months post-STZ injection compared to the non-diabetic mice (Table 1). LA attenuated the
increase of IL-6 in diabetic mice. In contrast, plasma TNF-α levels in diabetic and non-
diabetic mice were not significantly different at either time point.
3.4. Renal damage
All diabetic mice suffered from polyuria. LA supplementation showed a trend towards
improvement of this disorder, although the effect was not statistically significant (Table 1).
Kidney weight over body weight (KW/BW) in the diabetic mice was 40% higher than that
of non-diabetic mice (P<0.05). This change may partially reflect the reduced BW in diabetic
mice. Dietary LA significantly decreased the KW/BW ratio in diabetic mice (Table 1). The
daily urinary albumin excretion was markedly elevated in diabetic mice at 5 months after
STZ treatment and LA significantly attenuated albuminuria (Figure 2E).
The gross appearance of kidneys in diabetic apoE−/− mice was unaltered. Light microscopy
examinations revealed mesangium hypercellularity, nodular and diffuse MME, and rare foci
of mesangiolysis in diabetic mice without LA supplementation (Figure 3B). In contrast,
diabetic animals with LA had significantly reduced MME compared to diabetic mice
without LA (Figure 2F, 3C). Electron microscopy showed that glomeruli from diabetic mice
that did not receive dietary LA exhibited intracapillary lipid-laden mesangium and
mesangial expansion (Figure 3D). Peripheral glomerular capillaries were aneurysmatically
dilated and lost anchoring points to the mesangial cells (Figure 3E). No obvious alterations
of podocyte foot processes were detected in diabetic mice, possibly due to a very early stage
of diabetic nephropathy for our model (Gurley, et al., 2006). The tubulointerstitial
compartment in diabetic animals either with or without LA supplementation showed only
minimal non-specific changes. No significant morphological abnormalities were observed in
the control glomeruli with or without dietary LA (Figure 3A).
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3.5. Gene expression in the kidney
No obvious alterations of podocyte foot processes were detected in the diabetic mice, but the
glomerular expression of nephrin was down-regulated in the diabetic mice and LA restored
its expression (Table 2). In diabetic mice that did not receive LA, kidney expression of
transforming growth factor beta 1(Tgfb1) and connective tissue growth factor (Ctgf) was
increased at 20 weeks after injection of STZ (Table 2). Dietary LA significantly attenuated
the up-regulation of the genes. In contrast, changes in the expression of the collagen I and
collagen IV genes in diabetic animals were not significant. Rage (receptors for AGEs) was
increased in diabetic mice while LA supplementation reduced it.
Among the genes related to oxidative stress in the kidneys, Sod2 expression in diabetic mice
without LA was significantly lower than in non-diabetic mice, while p47phox and p22phox (a
regulatory subunit and a membrane associated flavocytochrome subunit for NADPH
oxidase) was increased. LA supplementation reversed these changes in diabetic mice.
Expression of glutathione perioxidase-1 (Gpx-1) showed a non-significant downward trend
in diabetic mice. Notably, the expression of genes for Lias and PDH phosphatase 2 (Pdp2)
decreased markedly to about 30% normal levels in the diabetic kidney. Dietary LA
significantly attenuated the down-regulation of Pdp2 expression, but further reduced the
Lias gene expression (Table 2).
3.6. Blood pressure
Systolic blood pressure in diabetic mice with or without LA supplementation were not
significantly different (105± 5 mmHg, n=8 vs. 114 ± 6 mmHg, n=7, P=0.08) at 5 month
after STZ injection in pre-STZ and co-STZ groups.
3.7. Dislipidemia and nephropathy in diabetic apoE−/− mice
High plasma cholesterol levels were observed in some but not all diabetic apoE−/− mice at
5 months after the onset of diabetes. Livers from mice with abnormally high plasma lipids
showed characteristic of steatohepatitis such as visible lipid droplets and inflammatory cells
(data not shown).
Daily albumin excretion was positively correlated with plasma glucose levels in the diabetic
apoE−/− mice that were not fed LA (R2=0.28, P<0.01, n=27) and to a lesser degrees in mice
treated with LA (R2=0.12, P=0.08, n=22). Plasma and kidney TBARS were positively
correlated with albumin excretion (R2=0.33, P<0.005, n=39 and R2=0.62, P<0.05, n=19,
respectively) only in the diabetic apoE−/− mice treated with LA.
Discussion
The current findings support previous observations that LA supplementation attenuated
hyperglycemia in diabetes and DN (Melhem, et al., 2002). We also report the novel
observation that regardless of the timing of LA administration (that is, before, at the same
time or one month after initiation of diabetes), LA supplementation significantly reduced
hyperglycemia, especially in post-STZ group where hyperglycemia was confirmed before
LA treatment. In addition, the observations of increased inflammatory cytokine and altered
renal gene expression suggested that inflammation played a role in DN development. The
data strongly implicate a therapeutic effect of LA on established diabetes.
The effects of LA on hyperglycemia and hyperglycemia-induced nephropathy are
incompletely understood (Winiarska, et al. 2008). LA exerts hypoglycemic effects, but
current evidence does not indicate that LA can function as an insulin secretagogue
(Khamaisi, et al., 1997). LA may exert hypoglycemic effects via other mechanisms
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including increased insulin sensitivity in type 2 diabetes (Jacob et al., 1999) and direct
binding site at the insulin receptor tyrosine kinase domain (Diesel, et al., 2007). Early
administration of LA may predispose the β cells to increased antioxidant capacity, enhance
their resistance to oxidative insults and consequently promote a better recovery after
exposure to STZ, leading to accelerated drop of hyperglycemia. Pancreatic β cells express
very low levels of antioxidant enzyme and are highly susceptible to free radical damage
(Grankvist, Marklund & Talijedal, 1981). Over-expression of antioxidant enzymes in β cells
enhances their resistance to oxidative stress and facilitates β cell recovery and even
regeneration in animals (George, et al., 2002).
Our findings of elevated urinary 8-isoprostane, a reliable marker of in vivo lipid
peroxidation (Morrow & Roberts, 1997), increased plasma and kidney TBARS, and
decreased erythrocyte GSH clearly indicate enhanced oxidative stress in diabetic mice. The
results are consistent with other investigations (Melhem, et al., 2002). Mitochondria are
believed to be a major organelles that produce superoxide and are also a primary target for
oxidative insult due to lack of protective histone and DNA repair ability (Shigenaga, et al.,
1994). Accordingly, mitochondrial superoxide production has been proposed as a single
unifying mechanism for diabetic complications (Brownlee, 2005). The active form of
MnSOD distributes in mitochondrial matrix and it works as the first line of defense against
superoxide and protects mitochondria from oxidative damage. In the current study, total
SOD activity and Sod2 in diabetic kidney cortex was markedly reduced whereas LA
supplementation restored SOD activity and Sod2 expression. These results suggest that LA
reinforces antioxidant defenses such as SOD2 and other superoxide dismutase, in order to
protect the kidney from damage by excessive superoxide production.
The observations of mesangiolysis and foamy glomerular mesangial cells in the diabetic
kidney of apoE−/− mice suggest a role for hyperlipidemia in the pathogenesis of DN.
However, hyperlipidemia alone cannot explain glomerular changes because kidneys of apoE
−/− mice with higher plasma lipid levels can be completely normal (Bruneval et al., 2002).
Similar fatty changes in mesangial cells and glomerular sclerosis were previously observed
by us in apoE−/−mice that were also lacking eNOS (Knowles et al., 2000). Reduced NO
bioavailability in diabetes is likely involved in the pathogenesis of mesangial changes and
may explain why LA significantly attenuated these changes (Nakagawa, et al. 2008).
The role of LA in inhibition of AGE formation in vivo is inconclusive. We postulate that LA
is a potential inhibitor of AGEs in two ways. First, LA improved glucose metabolism and
decreased methylglyoxal. Methylglyoxal is primarily generated from glyceraldehyde-3-
phosphate, an intermediate product in glycolysis pathway and has been considered the most
important agent leading to AGEs formation (Shinohara, 1998). LA feeding increases Krebs
cycle activity (Sudheesh, et al., 2009), leading to increased glyceraldehyde-3-phosphate is
consumption in the TCA cycle and increased ATP generation. As a result, less
glyceraldehyde-3-phosphate is available to form methyglyoxal. Our recently published
paper showed that ApoE−/− mice with genetically reduced lipoic acid production had
impaired PDC activity (Yi, et al. 2010). Secondly, LA prevents lipid peroxidation and
reduces aldehyde production
We observed that the endogenous production of LA is markedly compromised in diabetes as
judged by the reduction of Lias mRNA to less than 30% of normal levels. [Free LA in
plasma is very low and plasma lipoic acid cannot be quantified without special equipment;
instead, we examined mRNA level of Lias gene]. Although LA supplementation can
improve general health of the diabetic animals, including prevention of severe weight loss, it
failed to restore Lias gene expression, suggesting that glucose metabolism is responsible for
this reduction. The capacity to execute oxidative respiration is reduced in diabetes, as a
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consequence of a decrease in PDC activity. Reduction in LA, an essential cofactor of PDC,
could facilitate the switch from glucose oxidation to glycolysis in diabetes. Since the
decrease of endogenous LA production coincidentally reduces cellular availability of LA for
antioxidant defense, down-regulation of the Lias gene expression by high glucose may
accelerate diabetic complications. In addition, activity of mammalian PDC is regulated by
reversible phosphorylation-dephosphorylation of three specific serine residues of E1,
catalyzed by specific pyruvate dehydrogenase kinases (PDKs) and phospho-pyruvate
dehydrogenase phosphatases (PDPs). Our result showed that expression of Pdp2 in kidney
was significantly down-regulated during diabetes, whereas LA supplementation partially
restored Pdp2 expression. As a result, phosphorylation of PDC is increased, leading to
increased activity of PDC.
LA is not only a naturally occurring antioxidant but also a cofactor in several mitochondrial
enzymes that are involved in glucose oxidation and ATP generation. We could not ascribe
all effects of LA supplementation (e.g. altered expression of Lias gene) to antioxidant
property of LA. Thus, the beneficial effects of LA on diabetes and diabetic nephropathy
were most likely derived from combined antioxidant and metabolic regulations including
increase of glucose oxidation, rather than acting as an antioxidant alone.
In summary, our study showed that dietary LA supplementation not only exerts a better
hypoglycemia function if given prior to onset of diabetes but also LA effectively treats
established diabetes in mice. In addition, reno-protective effect of LA is equivalent in three
dietary groups irrespective of the time when treatment is initiated. The protective action of
LA is dependent on its function both as an antioxidant and as a regulator of glucose
oxidation.
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Changes in plasma glucose levels of diabetic and non-diabetic mice in pre-STZ group (A),
co-STZ group (B) and post-STZ group (C). Dietary lipoic acid (LA) was provided at 4
weeks before STZ treatment or at the same time with STZ or at 4 weeks after STZ,
respectively. The number of animals in each group is in parentheses. *P<0.05 against mice
without LA in the diabetic group (open squares). (D). Pancreatic β-cells survival rate in the
STZ-induced diabetic mice with or without lipoic acid supplementation in three dietary
groups. All results are expressed as mean ± SEM.
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Oxidative stress markers in the kidney cortex of apoE−/− mice with LA (black bars) and
without LA (white bars) at 5 months after onset of diabetes. (A) kidney Nε-(carboxymethyl)
lysine (CML) used for measurement of advanced glycation end products (B) kidney
thiobarbituric acid reactive substances (TBARS). (C) kidney total superoxide dismutase
activity (D). urinary 8-isoprostane. (E) daily urinary albumin excretion. (F) mesangial
matrix fraction was quantified as the region of positive periodic acid Schiff staining,
expressed as a function of total glomerular tuft area. The numbers inside bars indicate
number of animals. Results are expressed as mean ± SEM.
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Mesangial expansion and ultrastructural changes in diabetic apoE−/− mice at 5 month after
induction of diabetes. (A) non-diabetic mice without LA (B) diabetic mice without LA. (C)
diabetic mice with LA. PAS staining. Original magnification X200.
(D) Segmentally expanded mesangial areas due to accumulation of lipid laden cells,
presumably mesangial cells. (E) Aneurysmatic dilation of a peripheral glomerular capillary
(asterisk), and anchoring points between peripheral capillary walls and the mesangium were
lost.
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